Search results
Results from the WOW.Com Content Network
Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 b ... MRK stock is down 0.79% at $90.02 at the last check on ... Kris Jenner is selling original 'KUWTK' mansion for a shocking price.
The bad news: Its stock was down more than 10% in early trading, largely because of weaker-than-expected 2025 guidance. Merck reported $64.2 billion in sales for 2024, a 7% increase compared with ...
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug ...
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.